35.8 USD
-2.31 (-6.06%)
35.92 USD
+0.12 (+0.34%)
Overall TVTX gets a fundamental rating of 3 out of 10. We evaluated TVTX against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of TVTX have multiple concerns. While showing a medium growth rate, TVTX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
TVTX had negative earnings in the past year.
TVTX had a negative operating cash flow in the past year.
In the past 5 years TVTX always reported negative net income.
In the past 5 years TVTX always reported negative operating cash flow.
1.2 Ratios
TVTX's Return On Assets of -16.44% is fine compared to the rest of the industry. TVTX outperforms 78.87% of its industry peers.
TVTX has a Return On Equity (-120.36%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.44% | ||
| ROE | -120.36% | ||
| ROIC | N/A |
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TVTX's Gross Margin of 97.63% is amongst the best of the industry. TVTX outperforms 97.36% of its industry peers.
TVTX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for TVTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
2. Health
2.1 Basic Checks
TVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TVTX has been increased compared to 1 year ago.
TVTX has more shares outstanding than it did 5 years ago.
TVTX has a worse debt/assets ratio than last year.
2.2 Solvency
TVTX has an Altman-Z score of 1.35. This is a bad value and indicates that TVTX is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 1.35, TVTX is doing good in the industry, outperforming 64.72% of the companies in the same industry.
A Debt/Equity ratio of 4.23 is on the high side and indicates that TVTX has dependencies on debt financing.
The Debt to Equity ratio of TVTX (4.23) is worse than 80.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.35 |
ROIC/WACCN/A
WACC8.24%
2.3 Liquidity
A Current Ratio of 2.75 indicates that TVTX has no problem at all paying its short term obligations.
TVTX has a worse Current ratio (2.75) than 67.36% of its industry peers.
A Quick Ratio of 2.71 indicates that TVTX has no problem at all paying its short term obligations.
TVTX has a worse Quick ratio (2.71) than 66.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.71 |
3. Growth
3.1 Past
TVTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.91%, which is quite impressive.
TVTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 114.22%.
The Revenue has been growing slightly by 5.87% on average over the past years.
EPS 1Y (TTM)75.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
Revenue 1Y (TTM)114.22%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%162.11%
3.2 Future
Based on estimates for the next years, TVTX will show a very strong growth in Earnings Per Share. The EPS will grow by 29.30% on average per year.
Based on estimates for the next years, TVTX will show a very strong growth in Revenue. The Revenue will grow by 41.44% on average per year.
EPS Next Y87.9%
EPS Next 2Y46.91%
EPS Next 3Y36.7%
EPS Next 5Y29.3%
Revenue Next Year116.86%
Revenue Next 2Y72.36%
Revenue Next 3Y56.96%
Revenue Next 5Y41.44%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TVTX. In the last year negative earnings were reported.
TVTX is valuated quite expensively with a Price/Forward Earnings ratio of 55.13.
TVTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. TVTX is cheaper than 89.81% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of TVTX to the average of the S&P500 Index (23.79), we can say TVTX is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 55.13 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TVTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TVTX's earnings are expected to grow with 36.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.91%
EPS Next 3Y36.7%
5. Dividend
5.1 Amount
TVTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
35.8
-2.31 (-6.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners112.9%
Inst Owner Change0%
Ins Owners0.79%
Ins Owner Change-1.75%
Market Cap3.20B
Revenue(TTM)435.83M
Net Income(TTM)-88.54M
Analysts84.76
Price Target42.33 (18.24%)
Short Float %14.74%
Short Ratio6.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)143%
Min EPS beat(2)53.91%
Max EPS beat(2)232.09%
EPS beat(4)3
Avg EPS beat(4)68.35%
Min EPS beat(4)-27.29%
Max EPS beat(4)232.09%
EPS beat(8)4
Avg EPS beat(8)26.91%
EPS beat(12)6
Avg EPS beat(12)-40.48%
EPS beat(16)6
Avg EPS beat(16)-36.6%
Revenue beat(2)2
Avg Revenue beat(2)31.6%
Min Revenue beat(2)11.48%
Max Revenue beat(2)51.72%
Revenue beat(4)3
Avg Revenue beat(4)17.32%
Min Revenue beat(4)-0.02%
Max Revenue beat(4)51.72%
Revenue beat(8)6
Avg Revenue beat(8)9.84%
Revenue beat(12)9
Avg Revenue beat(12)2.67%
Revenue beat(16)9
Avg Revenue beat(16)-7.53%
PT rev (1m)0%
PT rev (3m)13.82%
EPS NQ rev (1m)-11.32%
EPS NQ rev (3m)52.97%
EPS NY rev (1m)0%
EPS NY rev (3m)58.33%
Revenue NQ rev (1m)-0.56%
Revenue NQ rev (3m)18.91%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)19.49%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 55.13 | ||
| P/S | 7.35 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 43.54 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.06
EYN/A
EPS(NY)0.65
Fwd EY1.81%
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS4.87
BVpS0.82
TBVpS-0.4
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.44% | ||
| ROE | -120.36% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 97.63% | ||
| FCFM | N/A |
ROA(3y)-36.55%
ROA(5y)-32.15%
ROE(3y)-416.31%
ROE(5y)-277.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.11%
GM growth 5Y-0.07%
F-Score6
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 89.32% | ||
| Cap/Sales | 11.21% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.75 | ||
| Quick Ratio | 2.71 | ||
| Altman-Z | 1.35 |
F-Score6
WACC8.24%
ROIC/WACCN/A
Cap/Depr(3y)142.8%
Cap/Depr(5y)123.81%
Cap/Sales(3y)28.66%
Cap/Sales(5y)21.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%140%
EPS Next Y87.9%
EPS Next 2Y46.91%
EPS Next 3Y36.7%
EPS Next 5Y29.3%
Revenue 1Y (TTM)114.22%
Revenue growth 3Y0.82%
Revenue growth 5Y5.87%
Sales Q2Q%162.11%
Revenue Next Year116.86%
Revenue Next 2Y72.36%
Revenue Next 3Y56.96%
Revenue Next 5Y41.44%
EBIT growth 1Y67.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year106.01%
EBIT Next 3Y45.04%
EBIT Next 5Y34.35%
FCF growth 1Y64.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.81%
OCF growth 3YN/A
OCF growth 5YN/A
TRAVERE THERAPEUTICS INC / TVTX FAQ
What is the ChartMill fundamental rating of TRAVERE THERAPEUTICS INC (TVTX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to TVTX.
What is the valuation status for TVTX stock?
ChartMill assigns a valuation rating of 3 / 10 to TRAVERE THERAPEUTICS INC (TVTX). This can be considered as Overvalued.
How profitable is TRAVERE THERAPEUTICS INC (TVTX) stock?
TRAVERE THERAPEUTICS INC (TVTX) has a profitability rating of 2 / 10.